Northland in Africa

The World Health Organizations (WHO) summarizes Africa’s pharmaceutical challenge as a trifecta consisting of:  lack of local productions facilities, the prevalence of substandard imported medications, and limited resources in proper storage.  African health agencies continue to struggle with the three big killer diseases on the continent: malaria, tuberculosis and HIV/AIDS. Globally, 60% of children under five who die of pneumonia, diarrhea, measles, HIV, tuberculosis and malaria are in Africa.

Overall, infectious disease remains as Africa’s largest public health challenge.  Common antibiotics for pneumonia (Amoxicillin, Penicillin, Fluoroquinolones ) and GI tract infectious (Ciprofloxacin, Metronidazole) remain a scarcity.  In addition, the demand for antimalarial medications (Artemether), antituberculosis (Isoniazid), and anthelmintic (Albendazole) far outstrips production and distribution capacity.  These diseases continue to prevail, and at times become epidemic, despite regional efforts by public health organizations to curtail infections.

Northland Bioscience, via its subsidiaries NBS Pharmaceuticals and NBS Medical, possesses the necessary production capacity and supply chain forecasting to provide a continuous supply of medications to the region. We work closely with local healthcare agencies to accurately assess product needs of a region; adjusting our manufacturing to help fill anticipated demand of specific products. Our highly trained staff not only monitor production quality but also work closely with the local communities to educate on proper storage, distribution, and administration of our products.